The drug was developed by Dr. Waldemar Priebe at The University of Texas MD Anderson Cancer Center and has shown promise in a Phase 1 clinical trial conducted by Reata Pharmaceuticals  NASDAQ RETA , Inc., including one durable complete response.
Dr. Waldemar Priebe of The University of Texas MD Anderson Cancer Center developed a drug that has shown promise in a Phase 1 clinical trial conducted by Reata Pharmaceuticals, including one durable complete response.